weight loss, GLP-1

Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,
GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs.
The Health Risks and Benefits of Weight-Loss Drugs
Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
Sweeping review suggests weight-loss drugs’ effect on 175 conditions
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected but contain surprises, too.
GLP-1 receptor agonists tied to risks and benefits beyond weight loss
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
Major Study Exposes New Health Risks of Weight Loss Drugs
A new study uncovers how widely used weight loss drugs like Ozempic impact various health conditions while posing notable risks.
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even dementia. But these drugs also come with risks that shouldn't be overlooked,
New Scientist14h
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...
Taking This Weight-Loss Medication Could Slash Dementia Risk, New Research Suggests
A new study found that GLP-1 medications like Ozempic can lower your risk for 42 conditions, including dementia. Here's what ...
GLP-1 weight loss medications pose challenges for c-stores. Here’s how retailers can respond.
Users of Ozempic and other drugs are shunning items like energy drinks and salty snacks, research shows. But there are ...
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
STAT1d
What can’t GLP-1s do? Study maps benefits while warning of uncommon risks
GLP-1 drugs like Ozempic have swept the world as effective therapies for far more than their original target of diabetes.
24/7 Wall St. on MSN6d
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...